Literature DB >> 22993162

A herpes simplex virus 2 glycoprotein D mutant generated by bacterial artificial chromosome mutagenesis is severely impaired for infecting neuronal cells and infects only Vero cells expressing exogenous HVEM.

Kening Wang1, Justin D Kappel, Caleb Canders, Wilmer F Davila, Dean Sayre, Mayra Chavez, Lesley Pesnicak, Jeffrey I Cohen.   

Abstract

We constructed a herpes simplex virus 2 (HSV-2) bacterial artificial chromosome (BAC) clone, bHSV2-BAC38, which contains full-length HSV-2 inserted into a BAC vector. Unlike previously reported HSV-2 BAC clones, the virus genome inserted into this BAC clone has no known gene disruptions. Virus derived from the BAC clone had a wild-type phenotype for growth in vitro and for acute infection, latency, and reactivation in mice. HVEM, expressed on epithelial cells and lymphocytes, and nectin-1, expressed on neurons and epithelial cells, are the two principal receptors used by HSV to enter cells. We used the HSV-2 BAC clone to construct an HSV-2 glycoprotein D mutant (HSV2-gD27) with point mutations in amino acids 215, 222, and 223, which are critical for the interaction of gD with nectin-1. HSV2-gD27 infected cells expressing HVEM, including a human epithelial cell line. However, the virus lost the ability to infect cells expressing only nectin-1, including neuronal cell lines, and did not infect ganglia in mice. Surprisingly, we found that HSV2-gD27 could not infect Vero cells unless we transduced the cells with a retrovirus expressing HVEM. High-level expression of HVEM in Vero cells also resulted in increased syncytia and enhanced cell-to-cell spread in cells infected with wild-type HSV-2. The inability of the HSV2-gD27 mutant to infect neuronal cells in vitro or sensory ganglia in mice after intramuscular inoculation suggests that this HSV-2 mutant might be an attractive candidate for a live attenuated HSV-2 vaccine.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22993162      PMCID: PMC3497698          DOI: 10.1128/JVI.01055-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  66 in total

1.  Generation of herpesvirus entry mediator (HVEM)-restricted herpes simplex virus type 1 mutant viruses: resistance of HVEM-expressing cells and identification of mutations that rescue nectin-1 recognition.

Authors:  Hiroaki Uchida; Waris A Shah; Ali Ozuer; Arthur R Frampton; William F Goins; Paola Grandi; Justus B Cohen; Joseph C Glorioso
Journal:  J Virol       Date:  2009-01-07       Impact factor: 5.103

2.  Cloning human herpes virus 6A genome into bacterial artificial chromosomes and study of DNA replication intermediates.

Authors:  Ronen Borenstein; Niza Frenkel
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-26       Impact factor: 11.205

3.  Sequence variability in clinical and laboratory isolates of herpes simplex virus 1 reveals new mutations.

Authors:  Moriah L Szpara; Lance Parsons; L W Enquist
Journal:  J Virol       Date:  2010-03-10       Impact factor: 5.103

4.  Human herpesvirus 6 encoded glycoprotein Q1 gene is essential for virus growth.

Authors:  Huamin Tang; Akiko Kawabata; Mayumi Yoshida; Hiroko Oyaizu; Takahiro Maeki; Koichi Yamanishi; Yasuko Mori
Journal:  Virology       Date:  2010-09-21       Impact factor: 3.616

5.  Numerous conserved and divergent microRNAs expressed by herpes simplex viruses 1 and 2.

Authors:  Igor Jurak; Martha F Kramer; Joseph C Mellor; Alison L van Lint; Frederick P Roth; David M Knipe; Donald M Coen
Journal:  J Virol       Date:  2010-02-24       Impact factor: 5.103

6.  Sexually transmitted diseases treatment guidelines, 2010.

Authors:  Kimberly A Workowski; Stuart Berman
Journal:  MMWR Recomm Rep       Date:  2010-12-17

7.  Herpes simplex virus 2 microRNA miR-H6 is a novel latency-associated transcript-associated microRNA, but reduction of its expression does not influence the establishment of viral latency or the recurrence phenotype.

Authors:  Shuang Tang; Andrea S Bertke; Amita Patel; Todd P Margolis; Philip R Krause
Journal:  J Virol       Date:  2011-02-16       Impact factor: 5.103

8.  Identification of viral microRNAs expressed in human sacral ganglia latently infected with herpes simplex virus 2.

Authors:  Jennifer L Umbach; Kening Wang; Shuang Tang; Philip R Krause; Erik K Mont; Jeffrey I Cohen; Bryan R Cullen
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

9.  Herpes simplex virus gD forms distinct complexes with fusion executors gB and gH/gL in part through the C-terminal profusion domain.

Authors:  Tatiana Gianni; Michele Amasio; Gabriella Campadelli-Fiume
Journal:  J Biol Chem       Date:  2009-04-22       Impact factor: 5.157

10.  Infection of neurons and encephalitis after intracranial inoculation of herpes simplex virus requires the entry receptor nectin-1.

Authors:  Sarah J Kopp; Ghazal Banisadr; Kelly Glajch; Ulrike E Maurer; Kay Grünewald; Richard J Miller; Pavel Osten; Patricia G Spear
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-05       Impact factor: 11.205

View more
  23 in total

1.  Displacement of the C terminus of herpes simplex virus gD is sufficient to expose the fusion-activating interfaces on gD.

Authors:  John R Gallagher; Wan Ting Saw; Doina Atanasiu; Huan Lou; Roselyn J Eisenberg; Gary H Cohen
Journal:  J Virol       Date:  2013-09-18       Impact factor: 5.103

2.  Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1.

Authors:  Kening Wang; Georgia D Tomaras; Sinthujan Jegaskanda; M Anthony Moody; Hua-Xin Liao; Kyle N Goodman; Phillip W Berman; Supachai Rerks-Ngarm; Punnee Pitisuttithum; Sorachai Nitayapan; Jaranit Kaewkungwal; Barton F Haynes; Jeffrey I Cohen
Journal:  J Virol       Date:  2017-09-12       Impact factor: 5.103

3.  Current status and prospects for development of an HSV vaccine.

Authors:  Christine Johnston; David M Koelle; Anna Wald
Journal:  Vaccine       Date:  2013-09-06       Impact factor: 3.641

4.  Intramuscular delivery of replication-defective herpes simplex virus gives antigen expression in muscle syncytia and improved protection against pathogenic HSV-2 strains.

Authors:  Fernando Diaz; Sean Gregory; Hiroshi Nakashima; Mariano S Viapiano; David M Knipe
Journal:  Virology       Date:  2017-10-22       Impact factor: 3.616

5.  Topical herpes simplex virus 2 (HSV-2) vaccination with human papillomavirus vectors expressing gB/gD ectodomains induces genital-tissue-resident memory CD8+ T cells and reduces genital disease and viral shedding after HSV-2 challenge.

Authors:  Nicolas Çuburu; Kening Wang; Kyle N Goodman; Yuk Ying Pang; Cynthia D Thompson; Douglas R Lowy; Jeffrey I Cohen; John T Schiller
Journal:  J Virol       Date:  2014-10-15       Impact factor: 5.103

6.  Genome Sequencing and Analysis of Geographically Diverse Clinical Isolates of Herpes Simplex Virus 2.

Authors:  Ruchi M Newman; Susanna L Lamers; Brian Weiner; Stuart C Ray; Robert C Colgrove; Fernando Diaz; Lichen Jing; Kening Wang; Sakina Saif; Sarah Young; Matthew Henn; Oliver Laeyendecker; Aaron A R Tobian; Jeffrey I Cohen; David M Koelle; Thomas C Quinn; David M Knipe
Journal:  J Virol       Date:  2015-05-27       Impact factor: 5.103

Review 7.  The challenge of developing a herpes simplex virus 2 vaccine.

Authors:  Lesia K Dropulic; Jeffrey I Cohen
Journal:  Expert Rev Vaccines       Date:  2012-12       Impact factor: 5.217

8.  Herpes Simplex Virus Organizes Cytoplasmic Membranes To Form a Viral Assembly Center in Neuronal Cells.

Authors:  Shaowen White; Hiroyuki Kawano; N Charles Harata; Richard J Roller
Journal:  J Virol       Date:  2020-09-15       Impact factor: 5.103

9.  Herpes simplex virus type 2 glycoprotein H interacts with integrin αvβ3 to facilitate viral entry and calcium signaling in human genital tract epithelial cells.

Authors:  Natalia Cheshenko; Janie B Trepanier; Pablo A González; Eliseo A Eugenin; William R Jacobs; Betsy C Herold
Journal:  J Virol       Date:  2014-06-18       Impact factor: 5.103

10.  Herpes Simplex Vaccines: Prospects of Live-attenuated HSV Vaccines to Combat Genital and Ocular infections.

Authors:  Brent Stanfield; Konstantin Gus Kousoulas
Journal:  Curr Clin Microbiol Rep       Date:  2015-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.